Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer. - Li C; Madan RA; Lee MJ; Lee S; Sato N; Rastogi S; Shrestha R; Aragon-Ching JB; Goswami M; Donahue RN; Cordes LM; Baj A; et al. (Journal for immunotherapy of cancer, 2026)